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ABSTRACT 
OBJECTIVE: To test the evidence that the risk of infection 
related to central venous catheters (CVCs) is decreased by anti-
infective coating or cuffing. 
DESIGN: Systematic review of randomized, controlled tri-
als comparing anti-infective with inactive (control) CVCs. 
INTERVENTIONS: Average insertion times were taken as 
a measurement of the length of insertion. Dichotomous data were 
combined using a fixed effect model and expressed as odds ratio 
(OR) with 95% confidence interval (CI95). 
RESULTS: Two trials on antibiotic coating (343 CVCs) had 
an average insertion time of 6 days; the risk of BSI decreased from 
5.1% with control to 0% with anti-infective catheters. There were no 
trials with longer average insertion times. In three trials on silver 
collagen cuffs (422 CVCs), the average insertion time ranged from 
5 to 8.2 days (median, 7 days); the risk of BSI was 5.6% with con-
trol and 3.2% with anti-infective catheters. In another trial on silver 
collagen cuffs (101 CVCs), the average insertion time was 38 days; 
the risk of BSI was 3.7% with control and 4.3% with anti-infective 
catheters. In five trials on chlorhexidine-silver sulfadiazine coating 
(1,269 CVCs), the average insertion time ranged from 5.2 to 7.5 
days (median, 6 days); the risk of BSI decreased from 4.1% with 
control to 1.9% with anti-infective catheters. In five additional trials 
on chlorhexidine-silver sulfadiazine coating (1,544 CVCs), the 
average insertion time ranged from 7.8 to 20 days (median, 12 
days); the risk of BSI was 4.5% with control and 4.2% with anti-infec-
tive catheters. 
CONCLUSIONS: Antibiotic and chlorhexidine-silver sul-
fadiazine coatings are anti-infective for short (approximately 1 
week) insertion times. For longer insertion times, there are no 
data on antibiotic coating, and there is evidence of lack of effect for 
chlorhexidine-silver sulfadiazine coating. For silver-impregnated 
collagen cuffs, there is evidence of lack of effect for both short- and 
long-term insertion (Infect Control Hosp Epidemiol 2002;23:748-
756). 
Central venous catheters (CVCs) are commonly 
used for hemodynamic monitoring, administration of med-
ication, and parenteral nutrition. The most frequently 
reported problems are insertion complications, occlusion 
of the catheter, vascular thrombosis, and catheter-related 
infections.1 Infection may be local or systemic, including 
thrombophlebitis, bloodstream infection (BSI), endocardi-
tis, and metastatic distribution (eg, osteomyelitis, endoph-
thalmitis, or arthritis).2,3 CVC-related bacteremia is a major 
cause of nosocomial BSI,4,5 with a reported incidence of 
approximately 5%.6 The consequences of these infections, 
in terms of morbidity, mortality, and additional healthcare 
costs, are of major importance.7 
A novel technologic approach to reduce CVC-related 
infection is the impregnation of catheters with antiseptic or 
antimicrobial agents, but clinical trials to assess the effica-
cy of these agents have produced inconsistent results.8,9 
Guidelines for the prevention of intravascular device-relat-
ed infections published by the Centers for Disease Control 
and Prevention proposed the use of impregnated catheters 
for adults with an unacceptably high rate of infection,10 but 
no consensus has been reached about the definition of 
such a rate. 
Recently, three studies reported important data on 
this subject. Two meta-analyses concluded that catheters 
impregnated with chlorhexidine-silver sulfadiazine 
decreased the incidence of catheter-related BSIs by 2.2% 
compared with inactive control catheters.11,12 However, a 
large, randomized, controlled trial showed that catheters 
treated with minocycline and rifampin were more effica-
cious in preventing BSI compared with those treated with 
chlorhexidine-silver sulfadiazine.13 In a few catheters with 
prolonged insertion times (> 1 week), an increased rate of 
BSI was observed for those treated with chlorhexidine-sil-
ver sulfadiazine compared with those treated with antibi-
otics. Although the numbers were small, it was suggested 
that these results should lead to a change in clinical prac-
tice for critical care patients.14 
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We undertook this study of randomized, controlled 
trials to quantify the relative efficacy of CVCs treated with 
different anti-infective agents and to identify factors that 
have an impact on the efficacy of these devices. 
METHODS 
Search Strategy 
An extensive search of the relevant literature in all 
languages was performed using MEDLINE (Data Star, 
PubMed, and KnowledgeFinder 4.19 to January 20, 2000), 
EMBASE (to January 12, 2000), and Cochrane Library 
(2000, issue I). Key words used alone or in combination 
included central venous catheter, infection, coated, impreg-
nated, subcutaneous cuff, antibiotic bonding, antibiotic-
coated, silver-sulfadiazine, chlorhexidine, and random. 
Reference lists of retrieved reports, review articles,10 and 
meta-analyses1115 were checked. Data from abstracts, let-
ters, review articles, and animal studies were not consid-
ered. 
Inclusion Criteria, Endpoints, and Definitions 
Included studies were full reports of randomized, 
controlled trials of adults that were published in peer-
reviewed journals and that compared any antiseptic- or 
antimicrobial-coated or antiseptic- or antimicrobial-cuffed 
CVC (anti-infective) with a similar uncoated or uncuffed 
device (control). Relevant trials had to report on catheters 
that were inserted percutaneously; those in which 
catheters were exchanged over a guidewire were not con-
sidered. 
One of two endpoints had to be reported in dichoto-
mous form according to the definitions provided by the 
original authors: catheter colonization per 100 catheters 
inserted and BSI per 100 catheters inserted. Catheter colo-
nization was considered as less important. It was defined as 
a documented growth from a proximal or distal catheter 
segment of either 15 or more colony-forming units (CFU) 
in a semiquantitative culture16 or more than 103 CFU in a 
quantitative culture.2 This definition was valid for the pur-
pose of this study regardless of whether cultures were 
obtained from the external surface only or from both the 
internal and the external surfaces of the catheters. BSI was 
considered as the primary endpoint in this context. It was 
defined as the presence of die same organism isolated from 
a (semi) quantitative culture of a catheter segment and from 
the patient's blood in die absence of another source of 
infection.5 This subgroup included patients with or without 
accompanying clinical symptoms (ie, sepsis). 
Scoring and Data Extraction 
All authors independently read the included articles 
and assessed their methodologic quality using the validat-
ed Oxford scale.17 There was a pre hoc agreement to 
include trials with randomization according to the patients' 
date of birth, hospital chart number, or alternate allocation, 
but to exclude trials without randomization (eg, historical 
controls). Allocated scores were compared, and consensus 
was reached by discussion. Data abstraction was per-
formed by one of the authors (BW) and independently 
cross-checked by the other two. 
Qualitative, Quantitative, and Subgroup 
Analyses 
For colonization, we calculated relative risk (RR) 
with 95% confidence interval (CI95).18 For BSI, which hap-
pens rarely, we calculated Peto odds ratio (OR); this is a 
more appropriate model when many trials show no 
events.19 We tested for statistical heterogeneity using a chi-
square test. A fixed effect model was used throughout 
because we combined data only when they were clinically 
homogeneous.20 
There was a pre hoc agreement that an absolute risk 
reduction of 2% or more to prevent BSI (corresponding to a 
number-needed-to-treat21 of 50 or fewer) was a clinically rel-
evant result2 and, therefore, would justify the use of anti-
infective CVCs. 
Sensitivity analyses were performed to test the 
impact of the duration of catheterization on the efficacy of 
these anti-infective devices to prevent BSI. For this pur-
pose, we extracted information on the average catheter 
insertion times from the original articles. 
RESULTS 
Trial Characteristics 
A total of 103 reports were screened. Twenty-seven 
were considered for inclusion and 4 were subsequently 
excluded due to the following: one had an inadequate con-
trol group22; one used historical controls23; one had inade-
quate endpoints24; and one25 described the same cohort 
reported in a previous article.26 Finally, 23 trials8'9,2646 pub-
lished between 1988 and 1999 including data on 4,660 
catheters (2,319 anti-infective and 2,341 control) were ana-
lyzed (Table 1). Eleven were conducted in an intensive care 
unit setting, four were conducted among oncologic 
patients, two were conducted among surgical patients, two 
were conducted among patients receiving total parenteral 
nutrition, and four were conducted among other patient 
populations. The average number of catheters per trial was 
194 (range, 20 to 680). The dropout rate of catheters varied 
between 0% and 49%. Average observation periods ranged 
from 2 to 147 days. The median Oxford score was 2 (range, 
1 to 5). In 18 trials, no attempt was made at blinding. 
Anti-infective catheters were treated with chlorhexi-
dine-silver sulfadiazine coating (12 trials, 1,456 catheters); 
silver-impregnated collagen cuffing (5 trials, 328 
catheters); antibiotic coating with teicoplanin, minocycline 
plus rifampin, vancomycin, or cefazolin (5 trials, 329 
catheters); and silver coating (2 trials, 206 catheters). One 
trial compared two devices with an inactive control group41; 
all other trials compared one device with a control. 
Qualitative and Quantitative Analyses 
Catheter Colonization. Catheter colonization 
was reported in 22 trials (3,902 CVCs) (Table 1). There was 
a large variability in event rates with both anti-infective and 
control catheters: 1.7% to 62% (average, 22%) for anti-infec-
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FIGURE 2. Impact of the average insertion times as reported in the original 
trials on the efficacy of anti-infective catheters to prevent bloodstream infec-
tion in the respective study. One study38 with no events has been excluded. 
95% CI = 95% confidence interval. 
tive catheters and 9.4% to 80% (average, 35%) for control 
catheters (Fig. 1, left). The scatter suggested improvement 
with anti-infective catheters. The data were heterogeneous 
(P< .001). When data from all trials were combined, the dif-
ference in favor of anti-infective catheters was statistically 
significant (RR, 0.61; CI95, 0.51 to 0.72). 
BSI. BS1 was reported in 18 trials (4,045 CVCs) 
(Table 1). There was a large variability in event rates with 
both anti-infective and control catheters: 0% to 7.8% (aver-
age, 2.9%) for anti-infective catheters and 0% to 13.8% (aver-
age, 4.7%) for control catheters (Fig. 1, right). In one trial, 
4 (13.8%) of 29 patients receiving an inactive control 
catheter had a BSI, whereas none of 26 receiving a silver-
impregnated collagen cuff catheter did.32 The scatter sug-
gested improvement with anti-infective catheters. The data 
were homogeneous (P = .329). When data from all trials 
were combined, the difference in favor of anti-infective 
catheters was statistically significant (OR, 0.63; CI%, 0.45 to 
0.87). 
Impact of Insertion Time on Anti-Infective 
Efficacy. Of all 18 trials that reported on BSI, one33 did not 
report on the average insertion time, one34 tested silver 
coating (ie, a technique that was not tested in any other trial 
reporting on BSI), and in one38 there was no BSI (ie, 0 
events). Thus, sensitivity analyses to quantify the impact of 
insertion time on anti-infective efficacy could be performed 
with data from 15 trials (16 comparisons) that tested antibi-
otic coating, silver-impregnated collagen cuffing, and 
chlorhexidine-silver sulfadiazine coating (Fig. 2; Table 2). 
In both relevant trials on antibiotic coating (343 
CVCs), the average insertion time was 6 days.26,41 The com-
bined risk of BSI decreased from 5.1% with control to 0% 
with anti-infective catheters (OR, 0.14; CI95, 0.04 to 0.51). 
There were no trials with longer average insertion times. 
In three of four trials on silver-impregnated collagen 
cuffs (422 CVCs), the average insertion time ranged from 
5 to 8.2 days (median, 7 days).3240'43 The combined risk of 
BSI was 5.6% with control and 3.2% with anti-infective 
catheters (OR, 0.54; CI95,0.21 to 1.36). In the fourth trial on 
silver-impregnated collagen cuffs (101 CVCs), the average 
insertion time was 38 days.31 The risk of BSI was 3.7% with 
control and 4.3% with anti-infective catheters (OR, 1.15; 
CI95, 0.16 to 8.49). One trial reported an average insertion 
time of 8.2 days.40 When data from this trial were pooled 
with the data from the trial with the longest average inser-
tion time,31 long-term efficacy was still not statistically sig-
nificant (incidence of BSI, 3.7% with control vs 2.1% with 
anti-infective catheters [OR, 0.56; CI95, 0.16 to 1.98]). 
In five of 10 trials on chlorhexidine-silver sulfadi-
azine coating (1,269 CVCs), the average insertion time 
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ranged from 5.2 to 7.5 days (median, 6 days).9'36'39-4144 The 
combined risk of BSI decreased from 4.1% with control to 
1.9% with anti-infective catheters (OR, 0.48; CI95, 0.25 to 
0.91). In the five other trials on chlorhexidine-silver sulfa-
diazine coating (1,544 CVCs), the average insertion time 
ranged from 7.8 to 20 days (median, 12 days).8-28'30'37'42 The 
combined risk of BSI was 4.5% with control and 4.2% with 
anti-infective catheters (OR, 0.94; CI95, 0.58 to 1.54). 
Adverse Events 
Twelve trials reported the presence or absence of 
adverse events.9'26'27'31"34'3840'42-43'45 There was some evi-
dence that cuffed catheters were more difficult to insert 
than control catheters,31 and that they extruded more 
often.32,40'43 No systemic allergic reaction or local hypersen-
sitivity was reported in any trial. 
Conclusions of the Original Authors 
In 12 studies (52%), the original authors concluded 
from their data that anti-infective catheters were use-
fu! 9,26,29,32,34,36,3841,43,45
 I n ten> they questioned the useful-
ness of such devices. The authors of one trial did not draw 
any conclusions.46 
DISCUSSION 
One of the proposed strategies to prevent CVC-relat-
ed infection is the antiseptic or antimicrobial coating or 
cuffing of catheters.47 BSI is the most relevant endpoint in 
this context. Two factors can be identified that have a major 
impact on the prevention of BSI with these catheters: inser-
tion time and type of anti-infective method. In previous 
meta-analyses on the antimicrobial efficacy of catheters 
treated with chlorhexidine-silver sulfadiazine, and from 
data on short-term trials only (2 to 10 days), there was a sta-
tistically significant decrease in BSI compared with control 
catheters (OR, 0.56; CI95, 0.37 to 0.84).111247 The authors 
concluded that these devices were effective in decreasing 
BSI. In our analysis, the result was similar for the subgroup 
of catheters treated with chlorhexidine-silver sulfadiazine 
and having short-term insertion (OR, 0.48; CI95, 0.25 to 
0.91). However, one additional important conclusion from 
this systematic review is that first-generation chlorhexi-
dine-silver sulfadiazine catheters are not efficacious when 
the average insertion time is longer than 8 days. 
Microorganisms in contact with plastic surfaces pro-
duce a protective, multi-layer biofilm within which they can 
survive.48 It is tempting to speculate that such a biofilm 
could suppress the anti-infective action of the treated 
catheters. Indeed, with average insertion times of approxi-
mately 1 week, 1 in approximately 50 catheters treated with 
chlorhexidine-silver sulfadiazine will not lead to a BSI, 
which would have been the case with inactive devices 
(absolute risk reduction, 2.2%) (Table 2). When average 
insertion times were twice as long (approximately 12 days), 
this number was 1 in approximately 300 (absolute risk 
reduction, 0.3%). These results are in agreement with both 
in vitro and in vivo studies.1328 In vitro, a steep exponential 
decrease in antimicrobial activity was shown during the 
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first week of insertion for devices treated with chlorhexi-
dine-silver sulfadiazine.28 In vivo, the antimicrobial activity 
of CVCs treated with chlorhexidine-silver sulfadiazine was 
shown to be time dependent.13 
With antibiotic coating, there was not one single 
case of BSI. The absolute risk reduction compared with 
inactive control catheters was 5.1%, suggesting that 
approximately 20 patients need to receive an antibiotic-
coated CVC for one patient not to develop a BSI who would 
have done so had they received inactive catheters. Thus, 
for short insertion times (ie, no longer than approximately 
1 week), there was some evidence from indirect compar-
isons that antibiotic coating was more efficacious than 
chlorhexidine-silver sulfadiazine impregnation. These 
data are consistent with the results of a recently published 
large, randomized trial13 in which CVC-related BSI was 
less likely in catheters coated with minocycline-rifampin 
(incidence, 0.3%) compared with catheters treated with 
chlorhexidine-silver sulfadiazine (incidence, 3.4%) with a 
median insertion time of 6 to 7 days. For both devices, the 
degree of short-term antimicrobial efficacy falls into our 
pre hoc definition of worthwhile prevention (ie, absolute 
risk reduction of & 2% corresponding to a number-needed-
to-treat of =s 50). However, data from the randomized 
trial13 and from our meta-analysis suggest that twice as 
many catheters treated with chlorhexidine-silver sulfadi-
azine, compared with antibiotic-coated catheters, need to 
be inserted to prevent one BSI. We do not know whether 
the difference in efficacy between these catheter types is 
due to the anti-infective substances per se, different meth-
ods of coating, or both. Impregnation with chlorhexi-
dine-silver sulfadiazine covers only the external surface of 
catheters. Some antibiotic coatings cover both the external 
and the internal surfaces of catheters. This may be associ-
ated with enhanced efficacy, as previously suggested,13 but 
needs to be formally tested. 
No long-term data on antibiotic-treated CVCs were 
available. In one study, a complete loss of activity for 
teicoplanin-coated catheters within 36 hours was report-
ed.27 Catheters treated with minocycline and rifampin may 
have antimicrobial activity extending up to 2 and possibly 
up to 4 to 6 weeks.25 This inconsistency may be interpreted 
as evidence of specific antibiotic activities. Further ran-
domized trials are needed to establish the effect of different 
antibiotic coating methods on the long-term anti-infective 
efficacy of CVCs. 
Silver-impregnated collagen cuffing did not prevent 
BSI, although one small trial with a short insertion time 
(average, 5 days) reported a borderline significant result in 
favor of the anti-infective catheters.32 In that trial, almost 
14% of patients who received a control catheter had a BSI, 
a rate that was much higher than that in any other trial (Fig. 
1, right). Because we have to assume that there is a rela-
tionship between the event rate in control catheters and the 
true underlying risk, it may be speculated that that trial 
studied patients at a particular high risk of infection. This 
was not the case (Table 1). However, small trials have been 
shown in other settings to overestimate the effect of an 
intervention.49 Because that trial was of limited size, it had 
no important weight in the combined analysis. 
We had to rely on average insertion times as report-
ed in the original studies to estimate the potential impact of 
insertion time on the efficacy of anti-infective CVCs. In 
some, the range of catheter duration for individual patients 
was wide. This is a limitation of our study. However, in the 
absence of valid randomized trials comparing different 
insertion times, these analyses remain the best we have. It 
would be helpful to confirm our results using individual 
patient data. 
Assuming that some anti-infective catheters prevent 
BSI if they are kept in situ for less than 1 week, we have to 
ask whether it is worthwhile to exchange these catheters 
regularly in chronically catheterized patients. There are 
three issues here: device, risk, and cost. Within the limita-
tions of our analysis, there was evidence for time depen-
dency with catheters coated with chlorhexidine-silver sul-
fadiazine. Thus, if those devices are to be used, there is an 
argument to replace them regularly, although it is not 
known whether one replacement per week is optimal. 
Systematic replacement of conventional CVCs through 
guidewire exchange every 3 days did not seem to reduce 
the risk of infection in a randomized trial.50 There was no 
evidence for time dependency of antibiotic-coated devices 
because no trials reporting on longer average insertion 
times could be retrieved. If the antimicrobial efficacy of 
antibiotic-coated catheters should indeed extend to 2 to 4 
weeks,13,25 an exchange of them after 7 days might not be 
necessary. However, this needs to be confirmed in ran-
domized, controlled trials. 
Risk includes mechanical complications during 
insertion,1 allergic reactions, and resistance acquisition. 
Insertion of cuffed catheters may be more difficult, and 
extrusion may occur.32-4043 Severe allergic reactions related 
to catheters coated with chlorhexidine-silver sulfadiazine 
have been described5152; however, no systemic allergic 
reactions were reported in the analyzed trials, most likely 
due to their low incidence. It is likely that the issue of 
increased risk of resistance concerns mostly antibiotic-
coated catheters. Furthermore, whether long-term expo-
sure of bacteria to disinfectants is associated with increas-
ing resistance or possible selective pressure to become 
antibiotic resistant remains to be determined.53 
Anti-infective catheters cost approximately twice as 
much as conventional catheters. To justify a change in clin-
ical practice, the increased cost incurred by a more fre-
quent use of a more expensive device must be balanced 
against the savings obtained by preventing BSIs. Catheters 
coated with chlorhexidine-silver sulfadiazine appeared to 
be cost-effective for short-term insertion (2 to 10 days).12 
Antibiotic-coated catheters were recommended for infec-
tion control in critically ill patients.14 However, the eco-
nomic impact of these CVCs should be evaluated to enable 
policy decisions to be made regarding their implementa-
tion in clinical practice. 
When inserted for no longer than 1 week, 1 in 
approximately 20 antibiotic-coated catheters and 1 in 
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approximately 50 catheters coated with chlorhexidine-sil-
ver sulfadiazine will not lead to a BSI, which would have 
occurred had they not been coated. As recently empha-
sized, this novel technology should be viewed as an adjunct 
to, rather than a substitute for, good infection control prac-
tices.54 Stringent application of guidelines to prevent 
catheter infection has been recognized as highly effica-
cious in critically ill patients.55 Anti-infective catheters are 
important in reducing the incidence of CVC-related infec-
tion, but further research is required to define the most 
efficacious method and the optimal time for device replace-
ment and to identify subgroups of patients who might ben-
efit most from this protective measure. Cost-effectiveness 
analyses of such interventions are also required. 
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